kabutan

Cuorips Inc.(4894) Summary

4894
TSE Growth
Cuorips Inc.
6,690
JPY
0
(0.00%)
Mar 16, 9:33 am JST
42.05
USD
Mar 15, 8:34 pm EDT
Result
PTS
outside of trading hours
6,687
Mar 16, 9:31 am JST
Summary Chart Historical News Financial Result
PER
PBR
11.2
Yield
ー%
Margin Trading Ratio
306.76
Stock Price
Mar 16, 2026
Opening Mar 16, 9:00 am
6,670 JPY 41.80 USD
Previous Close Mar 13
6,690 JPY 41.96 USD
High Mar 16, 9:11 am
6,780 JPY 42.52 USD
Low Mar 16, 9:00 am
6,670 JPY 41.80 USD
Volume
29,500
Trading Value
0.20B JPY 1.25M USD
VWAP
6716.17 JPY 42.15 USD
Minimum Trading Value
669,000 JPY 4,205 USD
Market Cap
0.06T JPY 0.35B USD
Number of Trades
120
Liquidity & Number of Trades
As of Mar 16, 2026
Liquidity
High
1-Year Average
1,051
1-Year High Feb 20, 2026
16,829
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 700 826,900 1181.29
Feb 27, 2026 1,000 818,500 818.50
Feb 20, 2026 900 872,800 969.78
Feb 13, 2026 1,100 725,700 659.73
Feb 6, 2026 0 701,100
Company Profile
Cuorips Inc. specializes in the development and commercialization of iPS cell-derived cardiomyocyte sheets.
Sector
Pharmaceuticals
Cuorips Inc. focuses on the development and commercialization of human iPS cell-derived cardiomyocyte sheets, working towards the practical application of regenerative medicine products. Through collaborative research with Osaka University and partnerships with major pharmaceutical companies, Cuorips has established advanced cell cultivation techniques. The company's products are expected to improve cardiac function and aid recovery from heart failure in patients with severe cardiac conditions. Utilizing its proprietary commercial cell culture and processing facility "CLiC-1", Cuorips also engages in Contract Development and Manufacturing Organization (CDMO) services and cell culture supernatant businesses. The CDMO services include development support and contract manufacturing, providing various cells as raw materials. The cell culture supernatant business effectively utilizes the liquid byproduct from the cell cultivation process. Cuorips aims to realize a wide range of regenerative medicine technologies, including the development of new catheter-based treatments and research on in vivo regeneration factor inducers.